Climb Bio
CLYM
22 hedge funds and large institutions have $46.8M invested in Climb Bio in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 0 closing their positions.
16% more funds holding
Funds holding: 19 → 22 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.87% less ownership
Funds ownership: 62.86% → 61.99% (-0.87%)
3% less capital invested
Capital invested by funds: $48.4M → $46.8M (-$1.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$416K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$43.4K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$25.3K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$24.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$228K |
| 2 |
Morgan Stanley
New York
|
-$184K |
| 3 |
Millennium Management
New York
|
-$8.17K |
| 4 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$5.92K |
| 5 |
BlackRock
New York
|
-$2.46K |
CLYM Hedge Fund Activity: Q2 2023 in Review
22 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q2 2023, worth a combined $46.8M — down 3.3% from $48.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CLYM positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Driehaus Capital Management, adding an estimated $416K. The largest seller was BML Capital Management, cutting an estimated $228K.
- 22 institutional investors held Climb Bio (CLYM) as of Q2 2023, up from 19 in Q1 2023.
- Funds reported $46.8M of Climb Bio stock for Q2 2023, down 3.3% quarter-over-quarter.
- 3 funds opened new Climb Bio positions in Q2 2023 and 0 closed out, a net change of +3 holders.
- The largest Climb Bio buyer in Q2 2023 was Driehaus Capital Management, an estimated $416K added.
- The largest Climb Bio seller in Q2 2023 was BML Capital Management, an estimated $228K sold.
Based on aggregated 13F filings for Q2 2023.